The Use of Drospirenone/Estetrol, Nomegestrol Acetate/Estradiol and Ethinylestradiol/Dienogest in Random Start Rapid Preparation of Endometrium Before Office Hysteroscopic Polypectomies: a Multicenter, Prospective, Randomized Study

The presence of a thin endometrium plays an important role in enabling the best conditions for hysteroscopic surgery. Recently, for this purpose, many studies have evaluated the effect of preoperative administration of a variety of drugs. We explored the efficacy of random started 14-day administration of Drospirenone/Estetrol or Nomegestrol Acetate/Estradiol or Ethinylestradiol/Dienogest, in rapid preparation of endometrium for hysteroscopic polypectomy.

开始日期2023-01-01

申办/合作机构

University of Palermo

[+1]

NCT06316219

/ Completed临床4期

The Use of Nomegestrol Acetate/Estradiol in Random Start Rapid Preparation of Endometrium Before Office Hysteroscopic Polypectomies: a Multicenter, Prospective, Randomized Study

The presence of a thin endometrium plays an important role in enabling the best conditions for hysteroscopic surgery. Recently, for this purpose, many studies have evaluated the effect of preoperative administration of a variety of drugs. We explored the efficacy of random started 14-day administration of Nomegestrol Acetate/Estradiol, in rapid preparation of endometrium for hysteroscopic polypectomy.

开始日期2023-01-01

申办/合作机构

University of Palermo

[+1]

NCT05264506

/ Terminated临床3期

A Phase 3, Open-label, Multi-center, Single-arm Study to Assess Contraceptive Efficacy and Safety of the Nomegestrol Acetate + 17β-estradiol Combined Oral Contraceptive (OG-8175A) in Premenopausal Females Aged 14 to 35 Years (Inclusive)

The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).

开始日期2022-02-17

申办/合作机构

Organon & Co.

100 项与醋酸诺美孕酮/雌二醇相关的临床结果

登录后查看更多信息

100 项与醋酸诺美孕酮/雌二醇相关的转化医学

登录后查看更多信息

100 项与醋酸诺美孕酮/雌二醇相关的专利（医药）

登录后查看更多信息

项与醋酸诺美孕酮/雌二醇相关的文献（医药）

2025-01-01·BMJ Case Reports

Petroclival meningioma regression after combined oestrogen and nomegestrol acetate interruption

Article

作者: Deprez, Louis ; Pintiaux, Axelle ; Lebeau, Julie ; Reuter, Gilles

Meningioma regression after progestin treatment interruption is already established. Zoely is a combined oral contraceptive including oestradiol and progestin (nomegestrol acetate). The effect of combined oestrogen with nomegestrol acetate on meningioma is currently unknown. We report the case of a woman in her early 50s under Zoely for 5 years who was diagnosed with a large petroclival meningioma. After cessation of Zoely, the patient showed clinical improvement and shrinkage of the tumour volume from 27.22 cm3 to 20.54 cm3 in 6 months. This is probably the first report of spontaneous meningioma regression after Zoely interruption.

2024-03-01·European journal of obstetrics & gynecology and reproductive biology: X

A review of the pharmacology, clinical outcomes, and real-world effectiveness, safety, and non-contraceptive effects of NOMAC/E2

Review

作者: Amisha Patel ; Franca Fruzzetti ; Rogerio Bonassi Machado ; Mitra Boolell ; Iñaki Lete

Selecting an appropriate oral contraceptive can be challenging for healthcare professionals due to the abundance of marketed contraceptive options with different clinical and real-world effectiveness and safety profiles. Nomegestrol acetate + 17β-estradiol (NOMAC/E2) is a combined oral contraceptive (COC) that inhibits ovulation by suppressing ovarian function by a 17-hydroxy-progesterone derivative and an estrogen identical to that endogenously produced by the ovaries. This narrative review examines clinical and real-world studies of NOMAC/E2 based on a background literature search using PubMed and Google Scholar. The review outlines the pharmacology of NOMAC/E2, including its progestational activity, pharmacokinetics, and effects on carbohydrate metabolism, lipid metabolism, and coagulation parameters, and summarizes key clinical efficacy and safety data that led to the approval of NOMAC/E2 in Europe, Brazil, and Australia. To help elucidate how NOMAC/E2 clinical trial data translate into a real-world setting, this review describes the effectiveness and safety of NOMAC/E2 in prospective studies that include over 90,000 users (half of whom received NOMAC/E2), outlining its effects on risk of thrombosis, menstrual bleeding patterns, weight, mood, acne, bone health, and patient quality of life. Non-contraceptive benefits of NOMAC/E2 for women with endometriosis, dysmenorrhea, or pre-menstrual dysphoric disorder are also discussed. These data demonstrate that NOMAC/E2 has a long half-life and rapid absorption, is effective at preventing unwanted pregnancies, and exhibits a favorable safety profile in both clinical trials and real-world settings. Importantly, NOMAC/E2 is not associated with increased risk of venous thromboembolism, a major safety concern of healthcare professionals for women receiving hormonal contraceptives. This review highlights NOMAC/E2 as a differentiated option among COCs and could help inform oral contraceptive choice to ultimately improve patient management and outcomes in real-world settings.

2024-01-02·EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE

Is the multinational, surveillance PRO-E2 study informative for all countries? The Italian data on VTE and contraceptive effectiveness

Article

作者: Cagnacci, Angelo ; Di Carlo, Costantino ; Bruni, Vincenzina ; Boolell, Mitra ; Fruzzetti, Franca

PURPOSE:

To evaluate whether the thromboembolic risk and contraceptive effectiveness of NOMAC-E2 observed in the PRO-E2 study can be extended to each participating country, as lifestyle, cardiovascular risk factors and prescribing habits may differ geographically. This analysis was performed on the PRO-E2 Italian subpopulation, where smoking habit and women over 35 years were more prevalent compared with the overall study population.

MATERIALS AND METHODS:

Data from NOMAC-E2 or levonorgestrel-containing COCs (COC_LNG) new users were descriptively analysed. Incidence rates of thrombosis (events/10,000 women-years [WY]) and the Pearl Index (pregnancies/100 WY) were calculated.

RESULTS:

Overall, 11,179 NOMAC-E2 and 8,504 COC_LNG users were followed up to 2 years (34,869 WY). The NOMAC-E2 cohort included more women over 35 vs. COC_LNG (37.7% vs. 31.8%; p = 0.001). A comparable low risk of combined deep venous thrombosis of lower extremities (DVT) and pulmonary embolism (PE) was observed in NOMAC-E2 (1.7/10,000 WY; 95% CI: 0.21-6.2) and COC_LNG users (6.6/10,000 WY; 95% CI: 2.4-14.4). Similar results were obtained by considering all thromboembolic events (VTE). Unintended pregnancies did not differ between NOMAC-E2 (0.12/100 WY; 95% CI: 0.06-0.21) and COC_LNG (0.15/100 WY; 95% CI: 0.08-0.26) cohorts.

CONCLUSION:

Despite the higher age and tobacco use, findings from the Italian subpopulation were broadly consistent with overall PRO-E2 results, confirming a similar low thromboembolic risk and high contraceptive effectiveness of NOMAC-E2 and COC_LNG.

SHORT CONDENSATION:

This subgroup analysis of the PRO-E2 study provides comprehensive epidemiological data on the use of combined oral contraceptives in a large Italian cohort, with a higher prevalence of women over 35 years and smokers. The study confirms the low thromboembolic risk and high contraceptive effectiveness of NOMAC-E2 pill.

项与醋酸诺美孕酮/雌二醇相关的新闻（医药）

2026-06-04

·乙酰水杨酸投研

梯瓦主要药品全球销售收入分析（2009年至2025年）

梯瓦制药（Teva）介绍及公司主要历史变迁梯瓦制药工业有限公司（Teva Pharmaceutical Industries Limited，NASDAQ: TEVA）是一家总部位于以色列的全球性医药公司，致力于开发及生产优质的非专利药物、创新的专科药物及活性药物成分，是全球药业领袖及世界最大的非专利药物生产商之一。 1901年，梯瓦在耶路撒冷由查姆·所罗门（Chaim Salomon），莫西·莱文（Moshe Levin）和伊沙克·埃尔斯坦（Yitschak Elstein）三位药剂师共同建立，在全国各地分销进口药物。命名为S.L.E。 1948年以色列政府成立后，以色列的医药市场稳定发展，梯瓦开始出口自己的产品。 1951年，梯瓦在Tel Aviv Stock Exchange (TASE)以色列特拉维夫证券交易所上市，上市的公司主体为Teva Middle East Pharmaceutical Chemical Works Company Ltd.。 1976年，Assia与梯瓦和Zori两家制药公司合并，成立了以色列最大的医疗保健公司——Teva Pharmaceutical Industries Ltd.。 1977年，梯瓦收购了荷兰的Orphahell，向欧洲扩张。 1982年，Kfar Saba生产工厂获得美国FDA批准生产。 1982年，梯瓦实现在纳斯达克市场上市。 1984年，US Hatch-Waxman Act法案通过，梯瓦开始进军仿制药领域。 1985年，梯瓦收购了美国宾夕法尼亚州的仿制药公司Lemmon，与W.R.Grace成立联营公司。 1988年至1989年，梯瓦收购了以色列第二大制药公司Abic，完成对以色列API生产商Plantex Ltd.的收购。 1992年，梯瓦收购了德国的GRYPharm。 1994年，梯瓦位于以色列Negev desert Ramat HovavAPI生产工厂Teva-Tech开始运营。 1995年，梯瓦收购了英国的APS/Berk，进军西欧市场。 1996年，梯瓦的首个用于多发性硬化症的创新药（Copaxone，醋酸格拉替雷，固派松）获得美国FDA批准。 2000年，梯瓦收购了加拿大最大的仿制药生产商Novopharm Ltd,，以及其在匈牙利的子公司Human，成为北美最大的仿制药供应商。 2001年，梯瓦用于多发性硬化症的创新药在欧盟获批。 2003年，梯瓦收购了印度的Regent Drugs Limited，收购后命名为Teva API India Ltd.。 2004年，梯瓦斥资34亿美元收购 Sicor，从而进入生产仿制药注射剂的生物仿制药领域。 2005年，梯瓦的抗帕金森病创新药（Azilect，甲磺酸雷沙吉兰，安齐来）在以色列和欧盟获批，2006年在美国FDA获批。 2006年，梯瓦以74亿美元收购IVAX Corporation，获得了大量仿制药及创新药产品。 2008年，梯瓦收购全球第四大仿制药品生产商 Barr Pharmaceuticals。该收购进一步巩固梯瓦在美国的领导地位，同时将大力强化其在欧洲和中东欧主要市场的地位。 2008年，梯瓦与日本的Kowa Company, Ltd.成立联营企业，向日本供应仿制药。 2010年，梯瓦以50亿美元的价格收购德国大型仿制药生产企业Ratiopharm公司，使梯瓦进一步巩固其在仿制药行业的龙头地位。 2011年，梯瓦收购了Cephalon及其子公司，增强其创新药业务。 2012年，梯瓦开始在NYSE（纽交所）上市。 2012年，梯瓦与Handok 成立联营企业，进军韩国市场。 2014年，梯瓦收购了美国的Labrys Biologics Inc.，获得了偏头痛预防和治疗领域相关管线。 2015年，梯瓦收购了 Auspex，增强其中枢神经系统领域的实力。 2016年，梯瓦与武田制药在日本成立联营企业。 2016年，梯瓦收购了Actavis Generics，扩充仿制药领域。同年，梯瓦收购了Anda Inc，为美国仿制药领域的分销商。2016年，梯瓦以400亿美元收购竞争对手Allergan的仿制药相关业务后，梯瓦制药一直背负着巨额债务，裁员是该公司大型重组计划的一部分。 2017年，用于治疗与亨廷顿病（HD）有关的舞蹈病及成人迟发性运动障碍（TD）的创新药物安泰坦（氘丁苯那嗪片）获得美国FDA批准。 2018年1月31日，梯瓦完成其美国以外销售的女性健康类产品OVALEAP，ZOELY，SEASONIQUE，COLPOTROPHINE以及其他品种ACTONEL的出售，以7.03亿美元的价格出售给CVC Capital Partners Fund VI。2018年7月1日，与P&G的合资公司PGT Healthcare解散，梯瓦将其持有的New Chapter Inc.的股份，以及在印度的OTC工厂转给了P&G。 2020年8月，梯瓦和Alvotech签署了5个生物仿制药的合作协议，梯瓦将拥有其在美国的独家权利。2020年7月，梯瓦与武田制药签署协议，将其与武田制药在日本的联营企业的仿制药和运营资产出售给Nichi-Iko。 2021年10月，梯瓦与MODAG GmbH签署协议，获得emrusolmin (TEV-’286) 和相关化合物(TEV-’287)的全球权益，拟用于多系统萎缩和帕金森病，具有针对退行性疾病如阿尔茨海默症等的潜力。管线完成了1b期临床试验。交易金额为3000万美元，以及未来里程碑付款及特许权费。 2023年11月26日，梯瓦与Biolojic Design Ltd.签署协议，获得全球范围开发、生产和商业化BD9的权益，未来可用于特应性皮炎和哮喘，梯瓦将支付首付款1000万美元，未来将可能有高达5亿美元的开发及商业里程碑付款。 2023年11月9日，梯瓦与Royalty Pharma plc签署协议，快梯瓦的奥氮平LAI （TEV- 749）的临床研究项目，Royalty Pharma将向梯瓦提供高达1亿美元的资金，用于资助奥氮平LAI （TEV- ‘ 749）的持续开发，Royalty Pharma和梯瓦有共同选择，将总融资金额增加到1.25亿美元。梯瓦将向Royalty Pharma支付里程碑付款，此外还有商业化后的特许权费。 2023年10月3日，梯瓦与赛诺菲签署协议，共同开发和商业化梯瓦的抗TL1A （TEV- ‘ 574）管线，一种用于治疗溃疡性结肠炎和克罗恩病两种炎症性肠病的新型抗TL1A疗法，目前处于2b期临床试验阶段。梯瓦将收到5亿美元的预付款，此外，梯瓦可能会获得高达10亿美元的开发和上市里程碑付款。两家公司将平均分担剩余的全球开发成本和主要市场净损益。梯瓦将领导该产品在欧洲、以色列和其他指定国家的商业化，赛诺菲将领导该产品在北美、日本、亚洲及其他地区的商业化。 2024年4月及9月，梯瓦与mAbxience就目前正在开发的包含抗PD-1的用于治疗多种肿瘤适应症的生物仿制药候选物达成战略许可协议及修订协议。mAbxience将开发和生产生物仿制药，梯瓦将领导包括欧洲和美国在内的多个全球市场的监管流程和商业化。梯瓦将分别支付首付款2000万美元和1500万美元。未来开发、监管、商业化里程碑付款约3.2亿美元。2024年3月28日，梯瓦和Launch Therapeutics， Inc.签署了临床合作协议，以进一步加速梯瓦的DARI-Duai-Action哮喘救援吸入器(ICS-SABA；TEV - 248)的开发。梯瓦还与Abingworth LLP的基金签订了协议。Abingworth和凯雷（Carlyle）支持的临床开发公司Launch Therapeutics，将在临床试验的运营执行和管理方面发挥主导作用。梯瓦将保留生产、美国监管互动和商业化的主要责任。TEV-‘248目前处于3期，用于治疗哮喘症状，可解决即时症状和长期炎症。Abingworth将向梯瓦提供高达1.5亿美元的资金，经监管部门批准，梯瓦将向Abingworth支付一笔里程碑付款，最高可达1.5亿美元，以及基于DARI销售额的成功费。梯瓦制药2025年主要动态财务业绩方面：2025年梯瓦制药实现总营业收入172.58亿美元，相比去年增长4.32%。其中，仿制药收入94.22亿美元，占总营业收入的54.59%；创新药及其他销售收入78.36亿美元，占总营业收入的45.41%；其他业务主要包括API生产、药品分销（Anda）、合作授权等业务收入，由于梯瓦年报中未进行详细分开披露，因此这里与创新药业务收入合并列示。国际审批方面：梯瓦于2025年官方网站披露的产品审批进度情况总结如下表，包括AVT05（戈利木单抗仿制药）用于类风湿关节炎等、AVT06（阿柏西普仿制药）用于血管性年龄相关星黄斑变性等、Selarsdi（乌司奴单抗仿制药）用于银屑病关节炎、克罗恩病等、Uzedy（长效利培酮）用于双相情感障碍、Epysqli（依库珠单抗仿制药）用于多发性夜间血红蛋白尿、重症肌无力等、Ponlimsi及Degevma（地舒单抗仿制药）用于骨质疏松症及骨巨细胞瘤等，以及TEV-749（奥氮平长效制剂）用于成人精神分裂症等。合作授权方面：梯瓦在2025年披露的合作授权方面的交易包括：与Samsung Bioepis关于Soliris仿制药Epysqli的合作授权、与Klinge Biopharma和Formycon关于阿柏西普仿制药的合作授权、与Biolojic Design关于BD9的合作授权、与上海复星医药关于抗PD1-IL2药物TEV-56278的合作授权，以及与Prestige Biopharma关于赫赛汀仿制药的合作授权，具体如下：梯瓦制药总体营业收入情况梯瓦制药于2007年至2025年期间的主要收入包括仿制药、创新药及其他业务。其他业务包括API生产、药品分销、OTC药物销售等，这些收入梯瓦年报里未单独披露，因此这里未进行单独列报。梯瓦制药主要是以生产销售仿制药为主，仿制药的销售收入占比虽然在2013年至2015年跌至50%以下（主要由于copaxone的大卖），在其他年份均超过了50%。创新药收入在研究期间早期经历了飞速发展，但在主要品种面临专利悬崖后，由于没有其他新品种进行补充，因此，创新药的销售收入在研究期间后期由于市场竞争大幅下降。梯瓦制药的总体营业收入在2018年开始大幅下降，主要由于市场竞争等原因，创新药受市场的冲击更为严重。梯瓦制药在2018年也在通过各种整合和合作力图挽回销售收入下降的趋势。2023年开始，总营业收入相比上一年均有所提升。梯瓦制药分类销售收入情况根据前面对梯瓦制药业务的梳理，梯瓦的仿制药业务一直是其传统业务，在研究期间早期通过大量并购扩张，实现仿制药业务的发展。同时，梯瓦也在开发创新药部门，梯瓦的财报在2009年才开始有对主要创新药品种的销售收入进行披露。根据梯瓦每年披露的各药品销售收入情况，按照药品性质分类的创新药销售收入数据如下图，梯瓦年报上没有披露的品种的销售收入统一归入其他类。梯瓦有披露数据的品种的销售收入之和占梯瓦总营业收入的16%~38%。加上一半的仿制药营业收入，剩余的其他业务收入大概占据了四分之一。由于数据有限，只能基于梯瓦披露数据的主要药品销售收入进行分析。在整个研究期间（2009年至2025年），梯瓦创新药品种是以神经系统药物为主，在前期也有呼吸系统药物、妇科药物以及OTC药物作为辅助。抗肿瘤药物在前期销售收入并不明显，但在2012年有了显著的提升。2018年，妇科药品实现对外出售。2022年以后，呼吸系统药物的销售收入未予单独披露。梯瓦制药披露的各药品销售收入情况根据每年梯瓦制药年报披露的主要药品销售收入情况整理的单品变迁情况见下图。可见在研究期间早期，梯瓦制药部门的产品主要为Copaxone（醋酸格拉替雷，固派松），2017年以后由于市场竞争，销售收入进入快速下滑阶段。呼吸系统药物ProAir（硫酸沙丁胺醇）及Qvar（倍氯米松双丙酸酯）也贡献了重要的部分，在研究期间，两品种的销售收入较为平稳，但在后期销售收入开始下降，2022年以后未予单独披露。在2018年对外出售前，女性健康品种的销售收入在研究期间一直比较稳定。Azilect（甲磺酸雷沙吉兰，安齐来）的销售收入在后续也在缓慢增长。Treanda/Bendeka（苯达莫司汀）虽然最早2008年获批，但在2012年才开始销售放量。2017年新推出的Austedo（氘丁苯那嗪，安泰坦）和2018年新推出的Ajovy（瑞玛奈珠单抗）上市后销售收入迅速上涨，成为梯瓦制药近年来的主要创新药品种。Copaxone的销售收入目前已低于这两个新品种。梯瓦制药2025年药品销售收入情况根据2025年披露的各药品销售收入数据，将各药品分类，未披露销售收入数据的药品全部归入其他类。梯瓦制药2025年实现总营业收入172.58亿美元，其中仿制药业务收入为94.22亿美元，占全部收入的54%。神经系统类创新药占比其次，实现销售收入35.92亿美元，占全部收入的21%。肿瘤类药物实现销售收入1.47亿美元，占全部收入的1%。其他业务（包括API、Anda、OTC等）实现收入40.97亿美元，占全部收入的24%。梯瓦制药2025年各品种销售收入如表。仿制药占比最高，2025年实现销售收入近95亿美元，占比54.59%。2017年获批新药Austedo销售收入22.60亿美元，占全部收入的13.10%。2018年获批新药Ajovy实现销售收入6.73亿美元，占总营业收入的3.90%。1996年获批老药Copaxone和2008年获批老药Treanda/Bendeka销售收入分别为4.68亿美元和1.47亿美元，占全部收入的2.71%和0.85%。 2023年获批的新药Uzedy销售收入2025年实现销售收入1.91亿美元，占全部销售收入的1.11%。以上也可以看出，梯瓦制药的创新药主要集中在神经系统药物。披露的各品类产品销售收入情况根据每年梯瓦制药披露的各品类产品销售收入情况整理的各单品销售收入变迁情况见下图。根据每年梯瓦制药披露的各品种销售收入情况整理，梯瓦制药于2009年至2025年的财报上披露有销售数据品种共有10个，其中包括神经系统药物品种7个，肿瘤药物品种1个，呼吸系统药物品种2个。梯瓦制药肿瘤类品种包括：Austedo（氘丁苯那嗪，安泰坦）、Ajovy（瑞玛奈珠单抗）、Copaxone（醋酸格拉替雷，固派松）、Uzedy（利培酮缓释注射混悬液）、Azilect（甲磺酸雷沙吉兰，安奇来）、Nuvigil（阿莫达非尼）以及Provigil（莫达非尼）。其中，2000年前上市的老药包括1996年获批的Copaxone，用于复发型多发性硬化症，为多肽醋酸盐，用于调节免疫，此品种非常成功，2013年达峰值销售额43.28亿美元，但2017年开始，由于受到市场竞争等原因，销售收入迅速下降，2025年销售收入降至4.68亿美元。1998年上市的老药Provigil，用于发作性睡病、特发性嗜睡等，为非典型的多巴胺再摄取抑制剂，销售后不久就被新推出的Nuvigil所替代。Nuvigil为2007年推出，为Provigil的R型异构体，Provigil为R和S型的混合外消旋体。但这两个品种推出后不是特别成功，2012年，Provigil的最高销售额为4.17亿美元。Novigil于2014年实现最高销售额为3.88亿美元。Azilect为2005年推出的耳熟能详的老药，雷沙吉兰，用于帕金森病，2014年最高销售额为4.28亿美元。其余3个品种均为较新推出的品种。2017年推出的Austedo，为丁苯那嗪的氘代产品，为单胺转运蛋白2的可逆抑制剂，用于亨廷顿舞蹈病以及迟发性运动障碍，2017年推出以后销售收入迅速增长，2025年实现销售收入22.60亿美元。Ajovy为2018年推出的新品，瑞玛奈珠单抗，为选择性结合降钙素基因相关肽的单抗，用于偏头痛，获批以来销售收入迅速增长，2025年实现销售收入6.73亿美元。Uzedy是2023年新推出的品种，为利培酮缓释的新剂型，可以实现每月给药1次，用于精神分裂症。这种给药方式对于精神分裂症患者来说带来了极大的便利，2025年实现销售收入1.91亿美元。综上可见，梯瓦制药的强项就在于神经系统药物，有很成功的Copaxone，近来推出的3个新品种也有很大的潜力。但由于在老药和新药中间存在断层，因此，在研究期间中期，老药Copaxone达到专利悬崖时，没有新药来承继和抵销老药专利悬崖带来的销售收入下降冲击，因此造成研究期间中后期销售收入的连年下滑。2017年和2018年才推出新品，到目前新品的销售收入仍处于爬升阶段，是否能够重新带来销售收入的进一步增长，我们拭目以待。梯瓦制药的肿瘤药物品种包括Treanda/Bendeka（苯达莫司汀），为2008年获批药物，用于B细胞非霍奇金淋巴瘤，主要为类嘌呤苯并咪唑环的双功能氮芥衍生物，氮芥及其衍生物可以形成亲电的碱性基团，与富电子的亲核基团形成共价键，造成DNA链间交联，从而杀死癌细胞。苯达莫司汀先推出的是Treanda，随后对剂型进行了改良，推出了Bendeka，2014年峰值销售额为7.67亿美元。目前肿瘤品种也处于销售收入下降区间。梯瓦制药推出的呼吸系统药物包括：ProAir（硫酸沙丁胺醇）和Qvar（倍氯米松双丙酸酯）。这两个品种均获批较早。Qvar为2000年获批品种，为肾上腺皮质激素，用于哮喘。ProAir为2004年获批，为选择性β2肾上腺素受体激动剂，用于支气管痉挛、哮喘、慢性阻塞性肺病。两个品种均为给药装置上的创新。Qvar于2016年达峰值销售额4.62亿美元，ProAir于2016年达峰值销售额5.65亿美元。总体来看，呼吸系统药物销售收入也处于下降区间，2022年开始，单品销售收入未予披露。梯瓦制药2025年各单品销售收入增长情况梯瓦制药2025年实现销售总销售收入172.58亿美元，相比2024年增长7.14亿美元（增长4.32%）。总体来看，销售收入的增长主要归因于Austedo、Ajovy以及Uzedy的销售收入增长。 Austedo在2025年实现销售收入22.60亿美元，相比2024年增长5.72亿美元（增长33.89%）。新品种Ajovy和Uzedy在2025年也实现了增长，Ajovy在2025年实现销售收入6.73亿美元，相比2024年增长了1.66亿美元（增长32.74%）。Uzedy是2023年新推出的品种，2025年实现营业收入1.91亿美元。这几个新的创新药品种仍处于销售收入的迅速爬坡阶段，相信未来有很大的增长潜力。梯瓦制药的销售收入下降主要来自于仿制药、老品种的销售收入以及其他业务。梯瓦正在努力整合和优化公司的运营，以降本增效提高经营效率。仿制药业务销售收入下降0.40亿美元（下降0.42%），Copaxone销售收入下降0.35亿美元（下降6.96%），Treanda/Bendeka的销售收入下降0.21亿美元（下降12.50%）。Copaxone从2017年销售收入大幅下降，一直到现在，销售收入下降的速度已略微放缓。Treanda、Bendeka由于本来销售收入也不多，因此销售收入的下降冲击对公司来说比较小。总结梯瓦制药自1901年成立以来，经历了一系列的变革，发展至今，成为集仿制药、创新药等生产销售的大型制药公司。梯瓦制药于1984年美国退出Hatch-Waxman法案后，大力发展仿制药业务，其后通过大规模的并购完成仿制药业务的扩张。梯瓦制药在发展仿制药的同时，也在进行创新药的研究，但相比仿制药业务，创新药业务的发展略显缓慢，可能主要归因于梯瓦的创新药聚焦于神经系统赛道。1996年推出Copaxone，2013年峰值销售额超过了40亿美元，之后再未推出销售如此成功的药物。虽然，2005年推出了2008年推出了Azilect（雷沙吉兰），2008年推出了抗癌药Treanda/Bendeka（苯达莫司汀），但销售收入均未超过10亿美元。由于中间面临Copaxone的专利悬崖，以及仿制药的竞争，梯瓦制药曾尝试通过大规模并购缓解营业收入的下降压力，但仍未能挽回颓势，梯瓦制药的销售收入在2018年开始陷入下降阶段，梯瓦也在尝试各种方法进行重组和整合，出售业务。2017年和2018年分别推出了创新药新品种Austedo和Ajovy，经过系列尝试，创新药新品种的销售收入也在逐步放量，2023年，梯瓦的总营业收入从下降中逆转，实现了正增长。2023年、2024年还有2025年销售收入相比上一年分别增长了6.17%、4.40%以及4.32%。从产品组合来看，创新药业务方面，梯瓦近年来推出的几个新品种Austedo，Ajovy以及Uzedy销售收入的增长可以抵销老品种Copaxone及Treanda/Bendeka的销售收入下滑，未来创新药业务也可以继续保持这种态势。仿制药的增长主要以来于梯瓦制药的内部整合和增效，2025年仿制药业务销售收入略有下降。其他业务仍依赖于梯瓦制药的进一步修整。总体来看，梯瓦制药已经逐渐拜托下降的趋势，开始慢慢的恢复，接下来可以进一步关注创新药的增长放量。梯瓦制药主要药品全球销售收入数据整理（2009年至2025年）详见B站（阿司匹林投研）或T宝（阿司匹林投研），加入知识星球（阿司匹林投研）可下载本文内的可编辑图表excel文件。

2024-02-13

·Endpoints

Organon shelves contraceptive with 'natural' estrogen

Organon’s attempt to revive a once-rejected “natural” contraceptive is over, a spokesperson confirmed to Endpoints News. The Merck women’s health spinoff has terminated a Phase III trial for NOMAC-E2 early due to “business reasons,” the spokesperson said. The company said the decision was unrelated to the drug’s safety. NOMAC-E2 was developed by Theramex, a women’s health business that was once part of Merck KGaA and Teva. The candidate has been touted as a “natural” alternative to other contraceptives using synthetic estrogen, because it contains a version of the hormone that’s structurally identical to estrogen produced in the body.

临床3期临床终止

2022-09-16

·ema

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022

12 new medicines recommended for approval EMA’s human medicines committee ( CHMP ) recommended 12 medicines for approval at its September 2022 meeting. The CHMP recommended granting a marketing authorisation for Beyfortus (nirsevimab) intended for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season (when there is a risk of RSV infection in the community). Beyfortus was supported through EMA's PRIority MEdicines (PRIME) scheme, which provides early and enhanced scientific and regulatory support to medicines that have a particular potential to address patients' unmet medical needs. See more information in the news announcement in the grid below. The committee adopted a positive opinion for Enjaymo * (sutimlimab) for the treatment of haemolytic anaemia (breakdown of red blood cells) in adult patients with cold agglutinin disease, a rare autoimmune disorder characterised by the premature destruction of red blood cells. Livtencity * (maribavir) received a positive opinion for the treatment of adults and paediatric patients with cytomegalovirus infection and/or disease that is refractory to one or more prior therapies. Cytomegalovirus is a type of herpes virus that commonly causes infection after a stem cell or an organ transplant. The committee adopted a positive opinion for Melatonin Neurim (melatonin) for the treatment of insomnia, a sleeping disorder affecting more than 10% of the European Union (EU) population. The CHMP gave a positive opinion for Mycapssa * (octreotide) for the treatment of acromegaly, a rare hormonal disorder where the body produces too much growth hormone. This causes body tissues and bones to grow more quickly, leading e.g. to the enlargement of the hands, feet, forehead, jaw or nose. The committee recommended granting a conditional marketing authorisation for Pyrukynd * (mitapivat) for the treatment of an inherited condition called pyruvate kinase deficiency, a rare genetic disorder characterised by the premature destruction of red blood cells. Zynlonta * (loncastuximab tesirine) received a positive opinion from the CHMP . This medicine is intended for the treatment of adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma, two types of cancer that begin in the lymphatic system when abnormal white blood cells grow. The committee adopted a positive opinion for the biosimilar medicine Ximluci (ranibizumab) for the treatment of neovascular age-related macular degeneration, a progressive retinal macular disease, causing gradual vision impairment, mainly in the elderly population. The CHMP recommended granting a marketing authorisation for Teriparatide SUN (teriparatide) for the treatment of osteoporosis in adults. Osteoporosis affects around 22% of women over the age of 50 in the EU. The recommendation followed a hybrid application, which relies in part on the results of pre-clinical tests and clinical trials of an already authorised reference product and in part on new data. The CHMP gave a positive opinion for the generic medicine Sorafenib Accord (sorafenib) for the treatment of hepatocellular carcinoma and renal cell carcinoma, two cancers that start in cells or tissues of the liver and kidney. The committee adopted a positive opinion for the generic medicines Teriflunomide Accord and Teriflunomide Mylan (teriflunomide), indicated for the treatment of multiple sclerosis, a chronic disease affecting the central nervous system. Recommendations on extensions of therapeutic indication for 11 medicines The committee recommended 12 extensions of indication for medicines that are already authorised in the EU: Adtralza , Biktarvy , Brukinsa , Evusheld , Exparel liposomal, Revolade, Skyrizi , Vaxneuvance , Veklury (includes two extensions of indication for two paediatric populations, see the COVID-19 update below), Xalkori and Yescarta . Withdrawals of initial applications The application for marketing authorisation for Exkivity was withdrawn by the respective applicant. This medicine was indicated for the treatment of a certain type of lung cancer. A question-and-answer document on the withdrawal is available in the grid below. The application for marketing authorisation for Sevsury was withdrawn by the respective applicant. This medicine was indicated for the treatment of progressive neuroendocrine tumours. A question-and-answer document on the withdrawal is available in the grid below. Re-examination concluded The CHMP confirmed its recommendation to suspend the marketing authorisations of several generic medicines tested by Synchron Research Services , a contract research organisation (CRO) located in Ahmedabad, India. This concludes the re-examination requested by the marketing authorisation holders for some of the medicines concerned. For more information, see the public health communication in the grid below. COVID-19 update Since the CHMP meeting in July, several recommendations related to COVID-19 vaccines and therapeutics were made. Authorising use of Nuvaxovid as a booster dose for adults who have had Nuvaxovid, an mRNA vaccine or an adenoviral vector vaccine as their primary vaccination. (The recommendation was made on 1 September 2022) Authorising two vaccines adapted to provide broader protection against COVID-19. Comirnaty Original/Omicron BA.1 and Spikevax bivalent Original/Omicron BA.1 are for use in people aged 12 years and above who have received at least primary vaccination against COVID-19. For more information, see the news announcement . (The recommendation was made on 1 September 2022) COVID-19 recommendations adopted during the present meeting of the CHMP : Authorising the adapted bivalent vaccine Comirnaty Original/Omicron BA.4-5 for use in people aged 12 years and above who have received at least a primary course of vaccination against COVID-19. This vaccine is an adapted version of the mRNA COVID-19 vaccine Comirnaty and targets the Omicron subvariants BA.4 and BA.5 in addition to the original strain of SARS-CoV-2. For more information, see the news announcement . Converting the conditional marketing authorisations of the COVID-19 vaccines Comirnaty and Spikevax into standard marketing authorisations . CHMP considered that the additional studies conducted by the companies as part of their post-authorisation obligations have provided ample information on the vaccines’ protection against COVID-19, as well as their quality and safety. For more information, see the news announcement . Approving a new manufacturing site in Dessau-Rosslau, Germany, for COVID-19 Vaccine Valneva . Authorising booster doses of Comirnaty for children from 5 to 11 years of age . Extending the use of COVID-19 therapeutic Evusheld for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen. Extending the use of COVID-19 therapeutic Veklury in two paediatric populations: Paediatric patients (of at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen or other non-invasive ventilation at the start of treatment. Paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. Safety update At its extraordinary meeting, on 2 September 2022, the CHMP endorsed the recommendation of the Pharmacovigilance Risk Assessment Committee ( PRAC ) and recommended that medicines containing high-dose nomegestrol (3.75 – 5 mg) or high-dose chlormadinone (5 – 10 mg) should be used at the lowest effective dose and for the shortest duration possible, and only when other interventions are not appropriate. In addition, low- and high-dose nomegestrol- or chlormadinone-containing medicines must not be used by patients who have, or have had, meningioma. For more information, see the news announcement . Agenda and minutes The agenda of the September 2022 CHMP meeting is published on EMA's website. Minutes of the September 2022 CHMP meeting will be published in the coming weeks. CHMP statistics Key figures from the September 2022 CHMP meeting are represented in the graphic below. *This product was designated as an orphan medicine during its development. Orphan designations are reviewed by EMA's Committee for Orphan Medicinal Products ( COMP ) at the time of approval to determine whether the information available to date allows maintaining the medicine’s orphan status and granting the medicine ten years of market exclusivity . Positive recommendations on new medicines Name of medicine Beyfortus International non-proprietary name (INN) nirsevimab Marketing-authorisation applicant AstraZeneca AB Therapeutic indication Prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants More information Beyfortus: Pending EC decision News announcement: New medicine to protect babies and infants from respiratory syncytial virus (RSV) infection Name of medicine Enjaymo INN sutimlimab Marketing-authorisation applicant Genzyme Europe BV Therapeutic indication Treatment of haemolytic anaemia in adult patients with cold agglutinin disease More information Enjaymo: Pending EC decision Name of medicine Livtencity INN maribavir Marketing-authorisation applicant Takeda Pharmaceuticals International AG Ireland Branch Therapeutic indication Treatment of cytomegalovirus infection and/or disease that is refractory to one or more prior therapies More information Livtencity: Pending EC decision Name of medicine Melatonin Neurim INN melatonin Marketing-authorisation applicant RAD Neurim Pharmaceuticals EEC SARL Therapeutic indication Treatment of insomnia More information Melatonin Neurim: Pending EC decision Name of medicine Mycapssa INN octreotide Marketing-authorisation applicant Amryt Pharmaceuticals DAC Therapeutic indication Treatment of acromegaly More information Mycapssa: Pending EC decision Name of medicine Pyrukynd INN mitapivat Marketing-authorisation applicant Agios Netherlands B.V. Therapeutic indication Treatment of pyruvate kinase deficiency More information Pyrukynd: Pending EC decision Name of medicine Zynlonta INN loncastuximab tesirine Marketing-authorisation holder ADC Therapeutics (NL) B.V. Therapeutic indication Treatment of adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma More information Zynlonta: Pending EC decision Positive recommendation on new biosimilar medicine Name of medicine Ximluci INN ranibizumab Marketing-authorisation applicant STADA Arzneimittel AG Therapeutic indication Treatment of neovascular age-related macular degeneration More information Ximluci: Pending EC decision Positive recommendation on new hybrid medicine Name of medicine Teriparatide SUN INN teriparatide Marketing-authorisation applicant Sun Pharmaceutical Industries Europe B.V. Therapeutic indication Treatment of osteoporosis in adults More information Teriparatide SUN: Pending EC decision Positive recommendations on new generic medicines Name of medicine Sorafenib Accord INN sorafenib Marketing-authorisation applicant Accord Healthcare S.L.U. Therapeutic indication Treatment of hepatocellular carcinoma and renal cell carcinoma More information Sorafenib Accord: Pending EC decision Name of medicine Teriflunomide Accord INN teriflunomide Marketing-authorisation applicant Accord Healthcare S.L.U. Therapeutic indication Treatment of multiple sclerosis More information Teriflunomide Accord: Pending EC decision Name of medicine Teriflunomide Mylan INN teriflunomide Marketing-authorisation applicant Mylan Pharmaceuticals Limited Therapeutic indication Treatment of multiple sclerosis More information To be published shortly Positive recommendations on extensions of indications Name of medicine Adtralza INN tralokinumab Marketing-authorisation holder LEO Pharma A/S More information Adtralza: Pending EC decision Name of medicine Biktarvy INN bictegravir / emtricitabine / tenofovir alafenamide Marketing-authorisation holder Gilead Sciences Ireland UC More information Biktarvy: Pending EC decision Name of medicine Brukinsa INN zanubrutinib Marketing-authorisation holder BeiGene Ireland Ltd More information Brukinsa: Pending EC decision Name of medicine Evusheld INN tixagevimab / cilgavimab Marketing-authorisation holder AstraZeneca AB More information Evusheld: Pending EC decision Name of medicine Exparel liposomal INN bupivacaine Marketing-authorisation holder Pacira Ireland Limited More information Exparel liposomal: Pending EC decision Name of medicine Revolade INN eltrombopag Marketing-authorisation holder Novartis Europharm Limited More information Revolade: Pending EC decision Name of medicine Skyrizi INN risankizumab Marketing-authorisation holder AbbVie Deutschland GmbH & Co. KG More information Skyrizi: Pending EC decision Name of medicine Vaxneuvance Common name pneumococcal polysaccharide conjugate vaccine (adsorbed) Marketing-authorisation holder Merck Sharp & Dohme B.V. More information Vaxneuvance: Pending EC decision Name of medicine Veklury INN remdesivir Marketing-authorisation holder Gilead Sciences Ireland UC More information Veklury: Pending EC decision Name of medicine Xalkori INN crizotinib Marketing-authorisation holder Pfizer Europe MA EEIG More information Xalkori: Pending EC decision Name of medicine Yescarta INN axicabtagene ciloleucel Marketing-authorisation holder Kite Pharma EU B.V. More information Yescarta: Pending EC decision Withdrawals of initial marketing authorisation applications Name of medicine Exkivity INN mobocertinib Marketing-authorisationapplicant Takeda Pharma A/S More information Exkivity: Withdrawn application Name of medicine Sevsury INN surufatinib Marketing-authorisationapplicant Hutchmed Europe B.V. More information Sevsury: Withdrawn application Outcome of referral re-examination Name of medicine Synchron Research Services More information Synchron Other updates List item Scientific advice and protocol assistance adopted during the CHMP meeting 12-15 September 2022 (PDF/230.36 KB) (new) Adopted First published: 16/09/2022 EMA/CHMP/SAWP/769857/2022

生物类似药疫苗抗体药物偶联物信使RNA

100 项与醋酸诺美孕酮/雌二醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	G03AA14	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
避孕	法国	Merck Sharp & Dohme Corp.	2007-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
痛经	临床2期	-	Merck Sharp & Dohme Corp.	2013-01-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05264506 (CTgov)	临床3期	避孕	3,055	NOMAC-E2 COC	淵壓顧範築淵獵顧壓壓 = 窪願夢鑰製鑰夢壓壓鑰淵鏇餘鑰簾膚壓壓鹹繭 (願齋糧網願醖鹽衊膚繭, 醖顧醖鹹廠鹹夢獵蓋範 ~ 鹹鹽鹽淵糧憲醖遞觸範) 更多	-	2025-11-21
NCT01656434 (P06448, CTgov)	临床3期	避孕	3,173	Placebo+NOMAC-E2 (NOMAC-E2)	繭餘艱淵製製繭蓋繭遞 = 鑰衊襯鬱窪網夢網製簾窪廠鏇鏇膚選製醖製憲 (簾積遞築憲獵艱製衊獵, 觸鹹淵鏇齋鏇淵醖艱範 ~ 淵範遞製範壓鑰襯齋廠) 更多	-	2015-03-17
				ethinylestradiol (EE)+NETA-EE+ferrous fumarate (NETA-EE)	繭餘艱淵製製繭蓋繭遞 = 壓襯蓋範鏇願夢廠遞鬱窪廠鏇鏇膚選製醖製憲 (簾積遞築憲獵艱製衊獵, 餘壓淵繭簾獵遞選簾範 ~ 衊艱鬱醖糧鏇衊衊構艱) 更多
NCT00511355 (P05764, CTgov)	临床3期	避孕	121	NOMAC-E2 (NOMAC-E2)	鹹繭膚夢廠餘構顧選壓(築選顧鹹鏇積鬱膚醖廠) = 窪顧簾膚憲鏇鑰鬱積鹹襯膚築蓋築襯艱壓壓淵 (選範廠壓蓋淵顧艱艱顧, 0.20) 更多	-	2011-08-30
				Levonorgestrel and Ethinyl Estradiol (LNG-EE)	鹹繭膚夢廠餘構顧選壓(築選顧鹹鏇積鬱膚醖廠) = 糧選壓觸膚鬱衊簾顧顧襯膚築蓋築襯艱壓壓淵 (選範廠壓蓋淵顧艱艱顧, 0.08) 更多
NCT00511433 (P05723, CTgov)	临床3期	避孕	48	NOMAC-E2 (NOMAC-E2)	壓選積製艱鬱範夢鏇餘 = 窪選廠觸襯鬱襯網網齋繭繭製獵齋廠廠簾網艱 (遞淵顧製簾範艱選築窪, 憲簾壓餘鏇襯艱願構選 ~ 窪網淵範簾遞蓋範鑰獵) 更多	-	2011-08-29
				DRSP-EE (DRSP-EE)	壓選積製艱鬱範夢鏇餘 = 鏇鏇鹹積積積遞壓糧鹹繭繭製獵齋廠廠簾網艱 (遞淵顧製簾範艱選築窪, 積構膚積網顧齋築醖蓋 ~ 願範鹹網壓淵壓鏇鑰選) 更多
NCT00413062 (P05722 \| 292002, CTgov)	临床3期	避孕	2,281	NOMAC-E2 (NOMAC-E2)	衊夢衊鏇壓觸鏇憲蓋衊 = 鏇糧鹽壓觸夢膚製餘構鹽觸壓糧積壓衊構艱繭 (衊淵夢淵遞鏇襯構窪糧, 鏇憲築積繭壓餘鏇蓋窪 ~ 顧遞觸艱範廠壓選願鬱) 更多	-	2011-08-29
				DRSP-EE (DRSP-EE)	衊夢衊鏇壓觸鏇憲蓋衊 = 夢淵壓糧鏇膚齋襯窪鏇鹽觸壓糧積壓衊構艱繭 (衊淵夢淵遞鏇襯構窪糧, 餘觸壓鏇築鹽鑰選繭繭 ~ 鑰觸構襯繭鏇窪顧艱簾) 更多
NCT01345786 (P06328, CTgov)	临床1期	-	158	Commercial NOMAC-E2 (Commercial NOMAC-E2, Part 1)	鏇餘餘齋衊鬱艱鹹積襯(獵醖夢糧網範鹽築範顧) = 構鏇鹹簾觸鹽壓廠憲醖蓋醖鑰遞壓糧網蓋壓夢 (鑰衊選網廠窪繭醖窪糧, 糧鏇顧觸觸築築鏇獵遞 ~ 餘醖遞壓遞艱築壓艱襯) 更多	-	2011-08-29
				NOMAC-E2 (Phase 3 NOMAC-E2, Part 1)	鏇餘餘齋衊鬱艱鹹積襯(獵醖夢糧網範鹽築範顧) = 艱壓鑰鹹鑰壓範餘築簾蓋醖鑰遞壓糧網蓋壓夢 (鑰衊選網廠窪繭醖窪糧, 窪壓顧艱窪觸艱鏇淵夢 ~ 築鹹鏇夢繭壓積遞範窪) 更多
NCT00511199 (P05724, CTgov)	临床3期	避孕	2,152	NOMAC-E2 (NOMAC-E2)	窪選積製鑰糧製願淵醖 = 鏇繭壓顧艱襯膚糧構遞襯蓋淵範衊遞醖觸繭築 (簾製觸鑰鑰製構夢鬱築, 壓廠製醖鹽膚獵願遞選 ~ 積襯積築簾糧顧蓋醖襯) 更多	-	2011-08-29
				DRSP-EE (DRSP-EE)	窪選積製鑰糧製願淵醖 = 鬱壓構膚鏇觸憲獵糧糧襯蓋淵範衊遞醖觸繭築 (簾製觸鑰鑰製構夢鬱築, 窪願鬱淵餘選襯獵壓夢 ~ 顧艱齋繭艱範壓餘獵鬱) 更多
NCT00511342 (P05765, CTgov)	临床3期	避孕	110	NOMAC-E2 (NOMAC-E2)	選繭齋獵餘製製廠鏇鏇(鏇鑰窪選膚願鹹淵鹽餘) = 淵繭膚窪醖製顧繭淵獵鏇淵繭鏇製築選鹹夢網 (積艱選窪遞廠蓋鑰積觸, 0.242) 更多	-	2011-08-29
				LNG-EE (LNG-EE)	選繭齋獵餘製製廠鏇鏇(鏇鑰窪選膚願鹹淵鹽餘) = 膚網廠獵簾壓顧範築繭鏇淵繭鏇製築選鹹夢網 (積艱選窪遞廠蓋鑰積觸, 0.269) 更多